Silobreaker.com    Log In
   My Page    Help   
360° SearchNetworkHot SpotsTrends
 
Advanced Search Options >>
Saturday, November 21, 2009 9:08 PM

Nucleoside

Type: Keyphrase
Name: Nucleoside
First Reported 20 hours ago - Updated 20 hours ago - 1 Documents (in Health)
Abdominal Adiposity Not Waning With Newer Antiretrovirals in France
Conference Reports for NATAP EACS - 12th European AIDS Conference November 11-14, 2009 Cologne, Germany &nbsp Adiposity Not Waning With Newer Antiretrovirals in France 12th European AIDS Conference, November 11-13, 2009, Cologne, Germany Mark Mascolini ... [National AIDS Treatment Advocacy Project - 20 hours ago]
First Reported 11/16/2009 - Updated 11/16/2009 - 1 Documents
Darunavir Troughs Lower With Raltegravir in Cross-Sectional Study
Darunavir trough concentrations proved significantly lower in people taking the protease inhibitor (PI) with raltegravir plus nucleosides than in people taking darunavir only with nucleosides [1]. Multivariate analysis confirmed that raltegravir was independently ... [National AIDS Treatment Advocacy Project - 11/16/2009]
First Reported 11/18/2009 - Updated 11/18/2009 - 1 Documents (in Health)
Oral HCV Protease Inhibitor R7227 plus Polymerase Inhibitor R7128 Suppresses HCV Viral Load without Interferon or Ribavirin
SUMMARY: Combination hepatitis C treatment using the nucleoside analog hepatitis C virus (HCV) polymerase inhibitor RG7128 (formerly R7128) plus the HCV NS3/4A protease inhibitor RG7227 (formerly R7227, also known as ITMN-191) produced potent antiviral ... [HIV and Hepatitis.com - 11/18/2009]
First Reported 11/02/2009 - Updated 11/03/2009 - 4 Documents (in Health)
INFORM-1 Results: Robust Antiviral Suppression Achieved with Combination of Nucleoside Analog Polymerase Inhibitor RG7128 and Protease Inhibitor RG722
BOSTON, Nov. 3 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) and Pharmasset, Inc. (Nasdaq: VRUS) today announced results from all patient cohorts of the INFORM-1 trial, an innovative Phase 1 study of two direct-acting antiviral (DAA) compounds ... [Yahoo! Canada - 11/03/2009]
First Reported 11/09/2009 - Updated 11/09/2009 - 4 Documents (in Medicine)
Pharmasset to Present at Lazard Capital Markets Healthcare Conference
PRINCETON, N.J., Nov. 9 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (NASDAQ: VRUS) announces management will present at the Sixth Annual Lazard Capital Markets Healthcare Conference. The conference will be held at the St Regis Hotel in New York City (November ... [PR Newswire - 11/09/2009]
First Reported 11/04/2009 - Updated 11/05/2009 - 2 Documents
Combination Therapy With A Nucleoside Polymerase (RG7128) And Protease (RG7227/ITMN-191) Inhibitor In HCV: Safety, Pharmacokinetics, And Virologic Results From INFORM-1
Boston, MA EJ Gane, SK Roberts, CA Stedman, PW Angus, B Ritchie, R Elston, D Ipe, PN Morcos, I Najera, T Chu, MM Berrey, WZ Bradford, M Laughlin, NS Shulman, PF Smith Auckland Clinical Studies, Auckland, New Zealand; The Alfred, Melbourne, Australia: ... [National AIDS Treatment Advocacy Project - 11/05/2009]
First Reported 10/26/2009 - Updated 10/26/2009 - 2 Documents
Inhibitex Announces Data Presentation at the 60th Annual Meeting
Inhibitex, Inc. INHX announced today that a poster presentation describing preclinical data on INX-189, the lead compound from its HCV nucleotide polymerase inhibitor program, will be presented by Dr. Joseph M. Patti, Chief Scientific Officer and Senior ... [Business Wire via MSN Money - 10/26/2009]
First Reported 11/02/2009 - Updated 11/02/2009 - 2 Documents
Pharmasset to Webcast an Investor Event from the AASLD Meeting - Reuters
PRINCETON, N.J., Nov. 1 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) today announced that it will webcast an investor event from the American Association for the Study of Liver Diseases (AASLD) on Monday, November 2, 2009 starting at 7:00pm ... [Software Developer - 11/02/2009]
First Reported 10/29/2009 - Updated 10/30/2009 - 2 Documents
Idenix (IDIX) Announces Presentations of IDx184 at AASLD in Boston
Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX) today announced presentations of data on IDX184, a once-daily novel liver-targeted nucleotide prodrug of 2'-methyl guanosine (2'MeG) for the treatment of HCV, at the annual meeting of the American Association ... [Street Insider - 10/30/2009]
First Reported 10/30/2009 - Updated 10/30/2009 - 1 Documents
Market Report -- Short Stories (IDIX)
Idenix Pharma downgraded to Above Average at Caris & Company; tgt lowered to $5 . Caris & Company downgrades IDIX to Above Average from Buy and lowers their tgt to $5 from $16. The firm notes that Idenix announced 3Q results as well as news that Novartis ... [Briefing.com via MSN Money - 10/30/2009]
First Reported 10/30/2009 - Updated 10/30/2009 - 1 Documents (in Biology)
Correlation between laboratory parameters and use or discontinuation of nucleoside analogues in the MONET trial
11th Workshop on Adverse Drug Reactionsand Co-morbidities in HIVPhiladelphia, USA, October 2009 Reported by Jules Levin 11th Workshop on Adverse Drug Reactions and Co-morbidities in HIV, Philadelphia, USA, October 2009 Andrew Hill, University of Liverpool, ... [National AIDS Treatment Advocacy Project - 10/30/2009]
First Reported 10/27/2009 - Updated 10/27/2009 - 1 Documents (in Medicine)
New HCV Polymerase Drug
Inhibitex Announces Data Presentation at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) Mon Oct 26, 2009 11:29am EDTINX-189 Exhibits Favorable Pharmacology Profile in Preclinical StudiesATLANTA-- Inhibitex, ... [National AIDS Treatment Advocacy Project - 10/27/2009]

Quotes

In a poster presentation titled "Voreloxin is Synergistic in In Vitro Combination with Cytarabine and Additive in Combination with Azacitidine, Decitabine and Clofarabine" (abstract number C222), Sunesis presented nonclinical data supporting the combination of voreloxin and cytarabine, a regimen currently used in Sunesis...
Sunesis Reports Data From Nonclinical Studies of Voreloxin at [Market Wire via MSN Money - 11/18/2009]
...and also allow for patients to be treated who are unable to take interferon based therapy," said Edward Gane, MD, lead investigator on this study. "The greater numbers treated and better success rates should eventually help reduce the future projected burden of end-stage liver disease for chronic HCV."
Study results of nucleoside polymerase and protease inhibitor combination therapy for HCV promising [News-Medical.Net - 11/04/2009]
(i) "Combination Therapy with a Nucleoside Polymerase (RG7128) and Protease (RG7227/ITMN-191) Inhibitor Combination in HCV: Safety, Pharmacokinetics, and Virologic Results from INFORM-1" Abstract #193: to be presented at the Meeting of the American Association for the StudyStudy of the Liver (AASLD) in Boston, Massachusetts, October 30...
INFORM-1 Results: Robust Antiviral Suppression Achieved with Combination of Nucleoside Analog Pol ... [Yahoo! Canada - 11/03/2009]
- About INFORM-1: www.clinicaltrials.gov (i) "Combination Therapy with a Nucleoside Polymerase (RG7128) and Protease (RG7227/ITMN-191) Inhibitor Combination in HCV: Safety, Pharmacokinetics, and Virologic Results from INFORM-1 Abstract #193: to be presented at the Meeting of the American AssociationAmerican Association for the Study of Liver Diseases (AASLD) in Boston, Massachusetts, October 30 - November 3, 2009."
INFORM-1 Results: Robust Antiviral Suppression Achieved with Combination of Nucleoside Analog Pol ... [Stockwatch - 11/03/2009]

More Content

All (161) | News (134) | Reports (6) | Blogs (2) | Audio/Video (0) | Fact Sheets (1)
sort by: Date | Relevance
Biocryst Pharmaceuticals (BCRX) Announces Prici... [BioSpace - 20 hours ago]
Abdominal Adiposity Not Waning With Newer Antir... [National AIDS Treatment Advocacy Project - 20 hours ago]
Kaletra QD Resistance Report: Lopinavir/ritonav... [National AIDS Treatment Advocacy Project - 20 hours ago]
Sunesis Reports Data From Nonclinical Studies o... [Market Wire via MSN Money - 11/18/2009]
Oral HCV Protease Inhibitor R7227 plus Polymera... [HIV and Hepatitis.com - 11/18/2009]
Entecavir (Baraclude) and Tenofovir (Viread) Re... [HIV and Hepatitis.com - 11/18/2009]
www.Xtremepicks.Com: Xtremepicks Alerts Novembe... [TMC Net - 11/17/2009]
BioCryst Announces Proposed Public Offering of ... [PR Newswire - 11/17/2009]
Resistant Bacteria Bring New Challenges to Anti... [PR-USA.net - 11/17/2009]
BioCryst Announces Proposed Public Offering of ... [Zibb - 11/17/2009]
Cyclacel Pharmaceuticals to Present Sapacitabin... [GlobeNewswire via MSN Money - 11/17/2009]
BioCryst Announces Proposed Public Offering of ... [Stockwatch - 11/17/2009]
Once-Daily Dosing Ups Risk of Stopping Antiretr... [National AIDS Treatment Advocacy Project - 11/16/2009]
Lower Intracellular Carbovir (Abacavir) Levels ... [National AIDS Treatment Advocacy Project - 11/16/2009]
Darunavir Troughs Lower With Raltegravir in Cro... [National AIDS Treatment Advocacy Project - 11/16/2009]
Study of Once-Daily Boosted Darunavir Monothera... [National AIDS Treatment Advocacy Project - 11/16/2009]
Later Year and Age Over 50 Tied to Better Respo... [National AIDS Treatment Advocacy Project - 11/16/2009]
MONET Paints Noninferiority Picture With Daruna... [National AIDS Treatment Advocacy Project - 11/13/2009]
Twice-Daily Darunavir/Ritonavir to Replace Doub... [National AIDS Treatment Advocacy Project - 11/13/2009]
Biota Holdings acquires Boston-based drug devel... [Proactive Investors.co.uk - 11/12/2009]
Access Pharmaceuticals – recent pull back could... [Proactive Investors.co.uk - 11/12/2009]
Biota (ASX:BTA) to acquire the antibacterial as... [BioPortfolio - 11/12/2009]
Biota (ASX:BTA) acquires the antibacterial asse... [BioPortfolio - 11/12/2009]
Access Pharmaceuticals Provides Update on MuGar... [Yahoo! Canada - 11/11/2009]
Access Pharmaceuticals Provides Update on MuGar... [Houston Chronicle - 11/11/2009]
InterMune, Inc. Q3 2009 Earnings Call Transcript [Seeking Alpha - 11/10/2009]
2 Oral HCV Drug Combination R7227+R7128 Without... [National AIDS Treatment Advocacy Project - 11/10/2009]
Pharmasset to Present at Lazard Capital Markets... [PR Newswire - 11/09/2009]
Pharmasset to Present at Lazard Capital Markets... [Freshnews.com - 11/09/2009]
Pharmasset to Present at Lazard Capital Markets... [Breitbart.com - 11/09/2009]
1 2 3 4 5
In Focus
  •  
PHASE 2, Peter Cook, Jean-Pierre Sommadossi, [more]
  •  
Pharmasset Inc, Inhibitex Inc, ViroLogic Incorporated, [more]
  •  
American Association for the Study of ..., US Securities and Exchange Commission, Food and Drug Administration, [more]
  •  
HIV/AIDS, Polymerase, Nucleotide, [more]
  •  
Boston (Massachusetts, United States), Auckland, Atlanta, [more]
  •  
United States, Germany, Australia, [more]
  •  
Medicine, Biology, Medication, [more]
  •  
Pharma & Biotech, Health, Chemicals & Plastics, [more]
NEJM — Collection Updates for HIV/AIDS, National AIDS Treatment Advocacy Project, Journal of Organic Chemistry, [more]
Content Volume
Network
Trends

Blogs

sort by: Date | Relevance
Access Pharma: A Smallcap Cancer Biotech Call O... [Biotech Sector and Stocks Analysis from Seeking ... - 05/28/2009]
Mike Havrilla submits:The cancer biotech space has attracted the interest of investors, traders, and diversified healthcare giants this year with Johnson & Johnson ...
Access Pharma: Low Valuation, Big Potential [Biotech Sector and Stocks Analysis from Seeking ... - 05/07/2009]
Mike Havrilla submits:With shares of Cell Therapeutics (NASDAQ:CTIC) staging the most astonishing comeback I have ever witnessed while rising from 8 cents at the ...
1

  •  
  •  
  •